Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Current Assets (2020 - 2025)

Historic Current Assets for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to $21.4 million.

  • Insight Molecular Diagnostics' Current Assets rose 34625.5% to $21.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.4 million, marking a year-over-year increase of 34625.5%. This contributed to the annual value of $11.8 million for FY2024, which is 991.77% up from last year.
  • Per Insight Molecular Diagnostics' latest filing, its Current Assets stood at $21.4 million for Q3 2025, which was up 34625.5% from $26.8 million recorded in Q2 2025.
  • Insight Molecular Diagnostics' 5-year Current Assets high stood at $62.8 million for Q1 2021, and its period low was $4.8 million during Q3 2024.
  • For the 5-year period, Insight Molecular Diagnostics' Current Assets averaged around $26.6 million, with its median value being $24.6 million (2022).
  • In the last 5 years, Insight Molecular Diagnostics' Current Assets plummeted by 7166.76% in 2024 and then surged by 45490.44% in 2025.
  • Over the past 5 years, Insight Molecular Diagnostics' Current Assets (Quarter) stood at $39.1 million in 2021, then plummeted by 34.76% to $25.5 million in 2022, then crashed by 58.11% to $10.7 million in 2023, then grew by 9.92% to $11.8 million in 2024, then soared by 81.89% to $21.4 million in 2025.
  • Its last three reported values are $21.4 million in Q3 2025, $26.8 million for Q2 2025, and $36.3 million during Q1 2025.